Physician profile
Clarisa Hammer
NPI 1386764504
$5,288.13
in general payments reported to CMS, 2019-2025
13 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $1,413 · 2021: $2,150 · 2022: $598 · 2024: $221 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $354.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,706.72 | 2019-2022 | |
| Medical Device Business Services, INC. | $1,301.18 | 2020 | |
| Myriad Genetic Laboratories, INC. | $221.04 | 2024 | Myrisk |
| Vector Surgical, LLC | $200.00 | 2019 | |
| Integra Lifesciences Corporation | $180.74 | 2022 | |
| Sientra, INC. | $169.90 | 2022 | |
| Smith+Nephew, INC. | $139.15 | 2021 | |
| Coopersurgical, INC. | $134.43 | 2019 | |
| Axogen | $89.93 | 2025 | |
| Innovation Technologies INC | $87.80 | 2020 | |
| Mentor Worldwide LLC | $25.52 | 2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Solventum Corporation | $17.84 | 2025 | V.A.C. Veraflo, Prevena |
| Kls-Martin L.P. | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarisa Hammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.